News

Matinas BioPharma Welcomes New Board Member and Funding Deal

Matinas BioPharma Welcomes New Board Member and Funding Deal

Introduction to Recent Developments at Matinas BioPharma

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) is making headlines with its latest announcement about a major agreement involving the acquisition of preferred stock and the appointment of a new board member. This strategic move promises to bolster the company's position as a leading biopharmaceutical entity focused on innovative health solutions.

Details of the Securities Purchase Agreement

The company has entered into a securities purchase agreement with a group of investors, allowing for the purchase of 3,300 shares of Series C Convertible Preferred Stock. This agreement includes warrants that give investors the potential to acquire up to 11,262,808 shares of common stock.

At an initial closing, investors successfully purchased 1,650 shares of the preferred stock, generating proceeds of $1.65 million. A second closing is contingent on stockholder approval, which will allow the company to receive an additional $1.65 million for the same number of shares and warrants.

The Mechanics of the Agreement

The shares of preferred stock are set to be convertible into common stock at a predefined price of $0.586. Notably, each preferred share can be converted into 1,706 shares of common stock. The accompanying warrants feature an exercise price of $0.6446 each and will become exercisable following shareholder approval, remaining valid for a period of five years.

The proceeds from this agreement are earmarked for general corporate needs, particularly aimed at lowering operating expenses and strategically advancing the development of MAT2203, a promising antifungal drug candidate.

Strategic Focus on MAT2203

Matinas BioPharma has positioned MAT2203 as a potential pivotal treatment for invasive fungal infections, offering a groundbreaking oral delivery alternative to existing intravenous therapies.

Overview of MAT2203

Traditional fungicidal agents, like amphotericin B, come with significant safety concerns, including renal toxicity and anemia, when administered intravenously. MAT2203's innovative lipid nanocrystal delivery technology aims to minimize these risks by providing targeted oral treatment, presenting a significant advancement in antifungal therapies.

Previous trials, including the Phase 2 EnACT study, have shown promising results, indicating that MAT2203 could play a crucial role in treating cryptococcal meningitis in HIV patients. The upcoming Phase 3 trial is expected to compare this oral therapy against standard care for patients suffering from invasive aspergillosis.

Appointment of Dr. Robin L. Smith

In a significant boost to the company’s leadership, Dr. Robin L. Smith has been appointed to the Board of Directors. Dr. Smith brings a wealth of experience as a medical doctor and business leader in the biopharmaceutical field.

Dr. Smith's Background and Impact

Having held various high-level roles across the industry, Dr. Smith has co-founded Spiritus Therapeutics and is an active player on multiple boards, including the International Board of Sanford Health. Her contributions to the field extend to numerous accolades and honors received for her leadership and innovations.

Dr. Smith holds degrees from prestigious institutions, including Yale University and the Wharton School of Business, fortifying her capability to guide Matinas through its next phase of growth effectively.

Acknowledgment of Leadership Changes

Alongside these promising developments, the company has announced the resignation of Herbert J. Conrad, the founding Chairman, who will be retiring from his position on the board after years of dedicated service. Matinas expresses its deep appreciation for Mr. Conrad’s leadership and contributions since the company's inception.

CEO Jerome D. Jabbour expressed enthusiasm about Dr. Smith’s appointment, highlighting her wealth of knowledge in medical and business realms, especially during this crucial period for Matinas BioPharma.

Looking Ahead

The company is committed to exploring additional strategic alternatives while managing costs during this transitional phase. Although the journey ahead may have uncertainties, Matinas BioPharma's leadership is optimistic about the potential outcomes of recent undertakings, including the approval processes kick-starting its proposed strategic directions.

Frequently Asked Questions

1. What recent agreement did Matinas BioPharma enter?

Matinas BioPharma entered a securities purchase agreement to sell preferred stock and warrants, totaling gross proceeds of $3.3 million.

2. Who is the new board member appointed?

Dr. Robin L. Smith has been appointed to the Board of Directors, bringing extensive experience in the biopharmaceutical industry.

3. What is MAT2203 and its significance?

MAT2203 is an innovative antifungal drug candidate that aims to provide an effective oral treatment for invasive fungal infections, overcoming limitations of existing therapies.

4. What are the intended uses of the funds from the agreement?

The funds are intended for general corporate purposes, particularly to reduce operating costs and advance strategic plans for MAT2203.

5. What does the future hold for Matinas BioPharma?

While exploring strategic alternatives, the company remains focused on reducing costs and advancing its product pipeline, particularly MAT2203.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 321

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 342

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

Embrace Pet Insurance Breaks Records in Volunteerism and Giving

Updated Category News Views 317

Embrace Pet Insurance Partners in Charity and Volunteerism Despite facing economic hurdles, charitable contributions across the nation showed remarkable resilience, highlighting the generosity of individuals and businesses alike. Recent reports reveal that charitable donations in the U.S. hit staggering heights, exceeding $557 billion in the last reporting year. Embrace...

Continue Reading
Sony's Innovative OLED Microdisplay Sets New Industry Standards

Updated Category News Views 210

Exploring Sony's Innovative OLED Technology Sony Semiconductor Solutions Corporation is about to change the landscape of augmented reality (AR) with the introduction of its groundbreaking ECX350F. This 0.44-type Full HD OLED Microdisplay is remarkable for its unique features, including the smallest pixel size in the industry and outstanding brightness. This innovation...

Continue Reading
Bascom Palmer Eye Institute Claims Top Spot in Medical Rankings

Updated Category News Views 269

Bascom Palmer Eye Institute's Unrivaled Recognition in 2025 For an impressive 24th consecutive year, Bascom Palmer Eye Institute has been honored as the premier ophthalmology hospital in the United States. This prestigious recognition, detailed in the 2025 U.S. News & World Report "Best Hospitals" rankings, underscores the institute's unwavering commitment to providing...

Continue Reading
Insights on Unusual Options Activity for Alphabet Inc.

Updated Category News Views 269

Unusual Options Activity Analysis for Alphabet Inc. Recent trends indicate that prominent financial players are adopting a bearish stance on Alphabet Inc. Our thorough analysis of options history for Alphabet (GOOGL) highlights 20 unusual trades, emphasizing a notable shift in market sentiment. Understanding Trader Sentiment Upon delving into the trade specifics, our...

Continue Reading
A Critical Juncture for uniQure Amidst Regulatory Challenges

Updated Category News Views 191

uniQure's Recent FDA Feedback The U.S. Food and Drug Administration (FDA) recently provided important insights to uniQure N.V. (NASDAQ: QURE) about its proposed gene therapy for Huntington’s disease. This feedback has led to a noticeable drop in the company’s stock price, reflecting heightened investor concern. Understanding AMT-130 AMT-130 is uniQure’s...

Continue Reading